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patients experience worsening of symptoms including in-
creased cough and sputum production and shortness of
breath. The present multicentre study was carried out in
an ambulatory setting in Germany, to compare and con-
trast the QoL of individuals with chronic bronchitis during
the stable phase and acute exacerbations. METHODS: Pa-
tients were admitted to the study if they developed an
acute episode of chronic bronchitis. Two hundred and
thirty five patients completed the St. George Hospital Res-
piratory Questionnaire (SGRQ) and the Nottingham Health
Profile (NHP) at study entry and during a stable phase sev-
eral months later. The study ran from October 1, 1996 un-
til March 31, 1998. RESULTS: The following hypotheses
will be tested:
• QOL will be poorer in men, in those with increasing
number of exacerbations in the previous 12 months
and in those who smoke and have exposure to other
risk and clinical factors.
• The more severe the AECB, and the more severe the
underlying condition, the poorer will be the quality
of life at the time of the AECB and the greater will be
the reduction in QOL from baseline.
• In general, the greater the number of potential prog-
nostic factors the poorer the QOL will be at the time
of both the AE and at ‘baseline’.
• Although the NHP and the SGRQ will show similar
trends the SGRQ will be expected to be more sensi-
tive: it will show a greater change from baseline to
AECB and will show a stronger association with clin-
ical factors such as the severity of the condition.
CONCLUSION: On the basis of the results of the analy-
ses, conclusions will be drawn which will clarify the effect
of exacerbations on the quality of life of people with CB.
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OBJECTIVES: To investigate cost-effectiveness and in-
cremental cost-effectiveness ratio for basic and immuno-
tropic therapy. METHODS: In cost-effectiveness analysis
the costs consist of expenditures for in-patient, out-
patient and emergency care, pharmacotherapy and indi-
rect expenditures for temporary invalidity of parents and
non-payment taxes. During one year prospective ran-
domized simultaneous investigation was conducted in
150 children with middle severe asthma. The patients of
the first group (50 children) were treated by sodium cro-
moglycate as basic therapy, the second group (50 chil-
dren), sodium nedocromil, the third group (50 children),
combination of sodium nedocromil and broncho-munal.
Cost-effectiveness criterion included the cost of one
asymptomatic day per year with determination clinico-
immunological indices. RESULTS: Investigation revealed
that the clinical effectiveness of basic and immunotropic
therapy were different. The most prolonged (341,4 
1,96 days) asymptomatic period was defined in patients
of the third group, the cost of one asymptomatic day was
the lowest (8,97  0,21 rubles) per year. Comparing
with the first group in the second one expenditures were
increased insignificantly (6,73 rubles) and effectiveness
was increased considerably (24,3 days), incremental
cost-effectiveness ratio was low (C/E  0,277). In-
verse dynamics of total expenditures (1990,17 rubles)
and increasing of treatment effectiveness (8,6 days, P 
0,01) was defined including broncho-munal therapy, in-
cremental cost-effectiveness ratio was 231,42. CON-
CLUSION: Increasing treatment effectiveness and de-
creasing expenditures was determined including broncho-
munal in complex therapy. Correlation between cost
and treatment effectiveness was rational in complex ther-
apy of child’s asthma with broncho-munal and sodium
nedocromil.
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OBJECTIVE: To test the hypothesis that health-related
quality of life is reduced as likelihood of asthma in-
creases. METHODS: The EuroQol EQ-5D questionnaire
and a modified European Community Respiratory Health
Survey questionnaire were administered by post to the
patients of two general practices in South Manchester,
UK in 1999. EQ-5D asks respondents to rate their func-
tion in 5 domains and also their overall health state on a
visual analogue scale (VAS). Valuations obtained from
the general public enable conversion of the domain re-
sponses to a single index value. RESULTS: More than
half (56%) of the subjects returned completed question-
naires. Significant trends towards lower health-related
quality of life (HRQoL) were seen with increasing age
and lower educational achievement. HRQoL was also
significantly worse in those considered ‘likely to have
asthma’ on the basis of their responses to the respiratory
symptom questionnaire. Mean domain derived score for
those likely to have asthma was 0.59 compared to 0.82
for those unlikely to be asthmatic (t  17.33 P 
0.0001). Mean self-reported VAS health states were 61.6
and 78.1 respectively (t  21.07 P  0.0001). Amongst
those considered ‘likely to have asthma,’ there was no
significant difference in HRQoL between those with and
without a confirmed diagnosis. CONCLUSION: The
EQ-5D has discriminant validity in the context of respi-
ratory disease. Use of the questionnaire in a postal survey
is an efficient way of obtaining HRQoL data from a pop-
ulation. It may be a useful tool to establish baseline
HRQoL data and subsequently to assess the impact of in-
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terventions in general practice. The addition of a disease-
specific HRQoL questionnaire in subjects who are thought
to be likely to have respiratory disease should be considered.
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OBJECTIVES: Chronic obstructive pulmonary disease
(COPD) is a major cause of morbidity and mortality in
Western society and its importance is increasing. The
long-term cost of COPD is currently unknown. The aim
of this study was to estimate the incidence based longi-
tudinal cost of COPD for the UK, from the payer’s per-
spective. METHODS: We examined 160 clinical and epi-
demiological papers and combined selected data in a
Markov model, with a time horizon of 20 years (40
stages of 6 months), and consisting of 29 exclusive health
states, primarily based on the evolution of forced expira-
tory volume in 1 second (FEV1), and history of hospital-
ization. Only sources that defined COPD in line with cur-
rent clinical guidelines were applied. Medical management
was obtained from database information (East of Lon-
don database) and 23 physician interviews. Health state
scores were obtained from a published cross-sectional
survey. Unit costs were obtained from official sources.
Costs are discounted at 6%. Uncertainty was estimated
through Monte Carlo analysis (1,000 runs). RESULTS:
The predicted 20 year cost for a patient starting in a mild
state (FEV1: 60–80%) or a moderate state (FEV1: 40–
59%) is £4,053 (95% CI  £3,743–£4,363) and
£11,746 (95% CI  £11,001–£12,491) respectively. The
cumulative number of Health State Adjusted Life Years is
respectively 12.10 years (95% CI  11.72–12.48) and
7.82 years (95% CI  7.51–8.13) over 20 years. CON-
CLUSIONS: Life expectancy is low, and the costs for pa-
tients starting in mild and moderate states are rather
modest, a finding that supports early diagnosis and inter-
vention. The model may serve as a framework to assess
the health economic impact of current strategies and new
treatment modalities for managing COPD.
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OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of emedastine, a new topical anti-hista-
minic, with topical levocabastine in Belgium, France,
Germany, Netherlands, Norway, Portugal and Sweden,
in the treatment of allergic conjunctivitis. METHODS: A
randomized, controlled, double-masked, multi-country
clinical trial compared the efficacy and safety of emedas-
tine 0.05% bid and levocabastine 0.05% bid. Economic
comparison of a strategy with Emedastine, and a strategy
with Levocabastine, including first line therapy and fail-
ure’s therapy was modelled using clinical trial results and
standard cost approach. Societal perspective was adopted
unless no indirect costs were estimated. Only drug costs
were considered for first line treatment costs. The costs
of failure were established from a panel of Ophthalmolo-
gists and General Practitioners and focused mainly on
out-patient resource utilization: visits, drugs, lab tests,
etc. RESULTS: A total of 221 patients (109 emedastine,
112 levocabastine) presenting with allergic conjunctivitis
were followed over 42 days. From day 7 to day 42, eme-
dastine-treated patients had less itching (P  0.001) and
less redness (P  0.001). The first line treatment failure
rate was 10% less (P  0.02) in emedastine-treated pa-
tients and they had an incremental 8.5 days (P  0.01)
without symptoms. Emedastine was as safe as levocabas-
tine and well tolerated. Emedastine strategy was found
economically dominating relative to levocabastine, i.e.
less costly, and more efficacious, in Germany, Portugal
and Sweden. In France, Belgium, the Netherlands and
Norway less than one € per extra day free of symptoms
has to be paid. Sensitivity analyses were conducted which
confirmed the robustness of our findings. CONCLU-
SION: Based on results of a randomized clinical trial, and
resources and costs associated with failure having been
estimated through expert interviews, our model found
that emedastine is a cost-effective alternative in the treat-
ment of allergic conjunctivitis.
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OBJECTIVE: This literature review identifies quality of
life (QOL), symptom and patient satisfaction (PS) mea-
sures that have been used effectively with adult and pedi-
atric asthma patients in clinical trials. METHODS: A
comprehensive literature review of French or English ar-
ticles, published between 1995 and 1999, was conducted
using Medline, Excerpta Medica and Mapi Research In-
stitute databases. RESULTS: 331 abstracts were assessed
for their relevance to asthma, QOL and PS. For adult
QOL, the literature review identified six generic, ten
asthma-specific, and two respiratory disease specific mea-
sures. A comparison of domains and psychometric prop-
erties yielded 3 generic measures (SIP, NHP, SF-36) and 4
